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Nuclear reprogramming has reshaped stem cell science and
created new avenues for cell-based therapies. The ability to
bestow any given phenotype upon adult cells regardless of
their origin is an exciting possibility. How can this powerful
tool be harnessed for the treatment of kidney disease? Many
approaches, including induced pluripotent stem cell (iPSC)
production, direct lineage conversion, and reprogramming
to a kidney progenitor, are now possible. Indeed, the
generation of iPSC lines from adult kidney–derived cells
has been successfully achieved. This, however, is just the
beginning of the challenge. This review will discuss the
fundamental concepts of transcription factor–based
reprogramming in its various forms, highlighting recent
advances in the field and how these are applicable to the
kidney. The relative merits of each approach will be discussed
in the context of what is a realistic and feasible strategy
for kidney regeneration via reprogramming.
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Nuclear reprogramming can be defined as a directed change
in cell phenotype that would not otherwise occur naturally.1,2
Nuclear reprogramming is famously exemplified by the
creation of induced pluripotent stem cells (iPSCs): embryonic
stem cell (ESC)–like cells generated from a variety of cell types
via the delivery of specific transcription factors.3–5 Originally,
Takahashi and Yamanaka3 showed that overexpression of just
four transcription factors could reprogram mouse embryonic
fibroblasts to iPSCs. These iPSCs expressed ESC markers, gave
rise to teratomas when transplanted subcutaneously, and con-
tributed to embryo development when injected into a blastocyst.
iPSC reprogramming experiments have been repeated and
extended to include a wide variety of donor tissues, including
skin, blood, fat, and skeletal myoblasts.6–9 A recent addition has
been the generation of iPSCs from kidney, either using adult
kidney mesangial cells10 or renal epithelial cells shed into the
urine.11 This and many other examples of transcription factor–
based reprogramming have raised the possibility that lineage
conversion between any two cell types, without the need to
return to pluripotency, may be possible. Indeed, it is possible to
reprogram directly to a variety of functional cell types, including
neurons, cardiomyocytes, and pancreatic b-islet cells.1,12,13 Despite
this impressive display of phenotypic conversion, the repro-
gramming to cells within the kidney lineages remains elusive.
This is an important issue to address, as the kidney has a limited
capacity to regenerate after injury. Chronic kidney disease is a
major global health problem, and there is an acute need to
develop treatment options that can restore endogenous kidney
function, as opposed to providing dialysis or transplantation.
Although researchers have extensively investigated the presence
of stem cells in the adult kidney,14–16 including the identification
of progenitors in the Bowman’s capsule able to replace podo-
cytes in vivo,17–19 to date there have been no reports of a postnatal
kidney progenitor cell capable of giving rise to all the cell
types of the mammalian nephron. As such, no new nephrons
can form in the adult mammalian kidney. Reprogramming
therefore represents an attractive strategy for the generation
of nephron progenitors in the postnatal mammalian kidney.
CROSSING THE BOUNDARIES: HOW DOES
REPROGRAMMING WORK?
Reprogramming need not be restricted to dedifferentiation
(return to a prior differentiative state) and certainly not
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restricted to the reimposition of a pluripotent state. There are
many reports of forced conversion between two unrelated
differentiated cell types that does not involve a pluripotent
intermediate state (termed lineage reprogramming or trans-
differentiation20). What appears critical for both dediffer-
entiation and transdifferentiation is the forced expression of
genes critical to the maintenance of the desired end-point
phenotype. In the case of iPSCs, these genes include the key
ESC pluripotency regulators, Oct4 and Sox2, and so it follows
for the generation of specific differentiated cell types that the
choice of reprogramming factors will be specific to that cell
type. This was indeed the case in an impressive example of
lineage reprogramming in vivo where Zhou et al.1 converted
mature exocrine cells of an adult mouse to glucose-responsive,
insulin-secreting pancreatic b-islet cells capable of ameliorat-
ing hyperglycemia in streptozotocin-induced diabetic mice.
They used the transcription factors Ngn3, Pdx1, and Mafa, all
of which are important for b-islet cell specification with
pancreatic developmental defects arising in their correspond-
ing mutant mice. More recently, additional studies have
reported the reprogramming of fibroblasts into cardiomyo-
cytes13 and neurons.12 Again, the reprogramming factors used
in these studies were lineage instructive for the end-point
phenotype, which supports the rationale for transcription
factor–based reprogramming.
The hematopoetic field is an ideal system to study lineage
conversion, owing to both the cellular diversity and the relative
ease of isolation and culture of these different cell types.
Lineage reprogramming is relatively advanced in the hemoto-
poetic field and predates much of the excitement generated by
the recent iPSC technology. Early experiments in this field
focused on the lineage-instructive role of GATA1 and PU.1 in
the erythroid–megakaryocyte and monocyte cell lineages,
respectively. Overexpression of GATA1 in monocytes caused
conversion to an erythroid–megakaryocyte lineage as assessed
by lineage-specific markers.21,22 Conversely, overexpression
of PU.1 in an erythroid–megakaryocyte cell line induced a
phenotypic conversion to a monocytic cell population,
facilitated via repression of GATA1.23 This phenotypic switch-
ing between monocytes and erythroid–megakaryocytes in
response to GATA1 or PU.1 overexpression highlights the
importance of the binary cell fate choices that exist during
normal development, as cross-antagonism between GATA1
and PU.1 proteins defines one of the most primitive steps in
hematopoietic development.24–26
CELL FATE DETERMINATION, WADDINGTON’S LANDSCAPE,
AND ATTRACTOR STATES
The concept that a differentiated cell can be reprogrammed
into another state has captured the imagination of the
biomedical community. How can this occur? During
embryogenesis, progressive development of epigenetic bar-
riers allows organized differentiation to occur, giving rise to a
highly complex organism. Unique chromatin marks such as
DNA methylation and histone acetylation control the activity
of specific genes, thereby acting as modulators of cell fate.
This has been conceptualized as the ‘epigenetic landscape’
first described by Conrad Waddington27 (Figure 1). It is using
this framework that the principles of not only differentiation
but also reprogramming can be understood.
Waddington depicted the differentiation of a pluripotent
cell as akin to a ball rolling from a hilltop through a landscape
of valleys to its final destination (Figure 1a). In doing so, the
ball will encounter alternative pathways, with its final
‘differentiated’ destination dependent on which pathway is
chosen. Similarly, a progenitor cell may have multiple fates
available to it. The differentiated phenotype it adopts will
depend upon the epigenetic barriers that either permit or
prevent certain outcomes. If a powerful fate-determining or
lineage-instructive transcription factor is activated in a
progenitor cell, or an alternative fate repressed by another
regulatory network, this will provide a potent attraction
toward a particular lineage.28 Once a ball enters such a stable
basin, it may not move further because of the barriers around
it (Figure 1a). This represents entry into an ‘attractor state’ or
a discrete cell phenotype resulting from the sum of the
transcriptional activity present in the cell at that time.29 Such
attractor states may be intermediate resting points during
differentiation or a final destination. Either way, an attractor
state is regarded as stable such that a less stable cell type will
converge upon a nearby attractor state over time.29,30 Once a
cell is in a particular attractor state, it is energetically
unfavorable for that cell to change its transcriptional activity
and move toward a different attractor state. However, if a cell
is forcibly disrupted via the imposition of a different gene
regulatory network, as occurs during reprogramming, it may
be pulled toward a different attractor state to reach another
energetically favorable resolution. Biological evidence for the
attractor state hypothesis was reported in a number of
studies.31–33 For example, treatment of HL60 cells with either
DMSO or all-trans retinoic acid results in transdifferentiation
into neutrophils, but this attractor state is reached via
different pathways in each case (Figure 1b). If the stimulus
was removed before the neutrophil phenotype was reached,
the cells reverted back to the initial phenotype, demonstrating
the strength of the initial attractor state.31
Given that an attractor state is a stable solution of gene
regulatory activity that results in a defined cell phenotype,
reprogramming must destabilize this gene regulatory network
to the point where the original attractor state is no longer
energetically favorable and the cell is forced to move into a
new attractor state. In the context of Waddington’s landscape,
reprogramming factors must force the ball over one or more
hills (epigenetic barriers) into an alternative valley (attractor
state) or back up a valley to an alternative attractor state
(Figure 1d). The key to efficient reprogramming is to know
which valleys lead to specific attractor states for specific cell
phenotypes and which combinations of lineage-instructive
genes are required for convergence to a given attractor state.
Gene expression studies or single-gene-perturbation experiments
can provide clues to appropriate lineage-instructive transcription
factors. Importantly, studies have shown that cells can converge to
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a single attractor state. For example, when hematopoetic pro-
genitor cells were FACS separated into Sca1very lo or Sca1very hi
and cultured in identical conditions, the Sca1 profile of the two
populations converged over time to the same hematopoetic
attractor state32 (Figure 1c). This means that reprogramming
can be imprecise: as long as the imposed transcriptional activity
brings the cell near the desired attractor state, the cell will
converge to that attractor state (Figure 1d). It also means that
there may be more than one possible combination of repro-
gramming factors that will work for different cell types: a finding
that has been demonstrated multiple times (Figure 1d).34–36
Because an attractor state is characterized by its gene
regulatory network, cells that are more closely related in
lineage are predicted to have more similar attractor states than
cells further apart in lineage (Figure 1e). This appears to be the
case when comparing the time and efficiency of reprogram-
ming the relatively distant fibroblasts with iPSCs (10–20 days;
0.5%) vs. hematopoietic reprogramming of pre-B cells to
macrophages (2–3 h; approaching 100% efficiency).37,38 Adult
progenitor cells such as myeloid progenitor cells or pro-B cells
can be reprogrammed to iPSCs with 300 times greater
efficiency than their more differentiated progeny.39 Similarly,
reprogramming efficiency is increased 50-fold when convert-
ing neural stem cells to iPSCs.40 Another prediction is that a
cell undergoing reprogramming need not dedifferentiate and
then redifferentiate; rather, it may directly transdifferentiate
with the intermediate cell phenotype expressing markers of
both the original and final cell types (Figure 1f). Hence, the
ball can be pushed over a hill from one valley to the next
without having to go back up to the valley and down another.
Indeed, reprogramming from pre-B cell to macrophage does
not involve the reexpression of pre-B cell precursor markers,
but instead a gradual shift in gene expression from the start to
end state.38 This is accompanied by the downregulation of
chromatin-associated factors, illustrating that reprogramming
involves chromatin reorganization.41–43
REPROGRAMMING THE KIDNEY: WHAT ARE THE OPTIONS?
Given the myriad of cell types affected during kidney disease,
what cell type should we aim to create? In diseases such as
bcde
abcd
defabc
+bc
+abc
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Attractor state
Pluripotent
Multipotent
Unipotent
Differentiated
cells
ac gh af
Figure 1 | The key principles of reprogramming as viewed within the analogy of Waddington’s landscape. Waddington’s landscape
effectively represents cell lineage specification and fate determination. It can also be used to illustrate the principles of the attractor
state and explain what might be required for reprogramming from one state to another. Waddington’s landscape has some key features.
(a) The landscape has direction: once the ball has committed to its descent, it cannot roll back up of its own accord. The more plastic the
cell, the higher up the hill it is. Hence, pluripotent is at the top, multipotent further down, unipotent below that, and differentiated at the
bottom. (b) The many hills and valleys represent the myriad of potential differentiative pathways available. Indeed, a particular basin may
be approached from more than one pathway. When transdifferentiating (moving from one cell type to another), you can take different
approaches to reach the same outcome. (c) Cells converge back into an attractor state, and hence reprogramming requires a considerable
shift away from that attractor basin. (d) Forced reprogramming requires the overexpression of genes instructive for an alternative attractor
state (e.g., abcd) to the starting attractor state. In this example, three different starting cells in different attractor states (expressing different
sets of genes, indicated as letters) require the overexpression of differing genes (indicated as þ ) to reach the same end-point attractor
state. Only some of these genes may be required, and hence different combinations of genes can reach the same destination. (e) It is easier
to reprogram from a related cell type (as shown by thick arrow) as opposed to a more distant attractor state (as shown by thin arrow).
(f) During reprogramming via the overexpression of lineage-instructive genes, there is no requirement to retrace a prior developmental
pathway. There can be direct conversion from one attractor state to another with the cell undergoing reprogramming displaying an
intermediate gene expression pattern between the two states during reprogramming.
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type 1 diabetes or Parkinson’s disease, replacement or
restoration of the function of a single cell type (b-islet cell
or dopaminergic neuron, respectively) may be sufficient to
rescue the phenotype. In contrast, the treatment of renal disease
would require the replacement or restoration of the many
functionally distinct cell types of the nephron. In addition to the
cellular complexity of the nephron, the pathology of the various
forms of kidney disease can vary widely. In some cases, this may
lend itself to distinct approaches for distinct disease presenta-
tions, but where complete nephron replacement is required a
large number of different cell types would be needed. It would
not seem feasible to generate each of these via reprogramming
and then redeliver all in vivo, nor would it seem feasible to
generate so many different cell types with the one in vivo
reprogramming strategy as each phenotype would require
different genes to elicit the appropriate attractor state. Ideally,
the creation of a nephron stem/progenitor cell population
would circumvent this problem by giving rise to all the cell types
of the nephron. Subsequent differentiation to multiple end
points would then be possible. Even here, there is more than
one strategy for induction. These include directing the
differentiation of a pluripotent stem cell toward a renal lineage
or dedifferentiating/transdifferentiating an adult cell directly to a
renal cell. For each of these options, there are a variety of
starting and target cell options, as illustrated in Figure 2.
In the case of directed differentiation to a renal lineage, the
best starting cell population would be patient-derived iPS
cells, which represent a genetic match (see Table 1). The
recent studies by Song et al.10 and Zhou et al.11 have for
the first time demonstrated that it is feasible to take an
adult kidney-derived cell back to a pluripotent state. This
observation, in and of itself, does not provide a way of
treating kidney disease. An iPSC derived from a mesangial
cell is likely to be functionally equivalent to an iPSC derived
from blood or skin, and it is easier to obtain patient samples
for the latter. There is some evidence of a retention of
epigenetic memory, suggesting that a kidney cell–derived
iPSC is more easily returned to the kidney than a neural-
derived iPSC and vice versa;44 however, this may represent
incomplete reprogramming. Even if this is the case, the
delivery of undifferentiated iPSCs or hESCs back into a
patient would result in teratoma formation, and thus onward
differentiation from the iPSC state is required. The literature
is reporting an increasing number of protocols for the
directed differentiation of human pluripotent cells (ESCs and
iPSCs) toward a variety of lineages and cell types. Perhaps of
importance for the kidney is the reported success of directed
differentiation of human ESCs and iPSCs to specific
hematopoietic lineages.45,46 The hematopoietic system is
mesodermal in origin and arises from the intermediate
mesoderm, as does the kidney. Piggybacking on some of the
early steps of blood differentiation may open the way for
directed differentiation to kidney cell types. There have also
been a small number of reports indicating that kidney may be
a feasible destination based upon the induction of appro-
priate gene expression in mouse ESCs treated with
RA/Activin-A and BMP747 and evidence for spontaneous
formation of Podxl1þ glomerular structures in teratomas
formed from human ES cells.48 As encouraging as these
studies are, it is important to note that the differentiated cells
are not analogous to their in vivo counterparts. As such,
further optimization of these procedures is necessary before
stepwise differentiation of the mesoderm into functional
kidney cells can be claimed.
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Figure 2 | The application of reprogramming to the kidney, indicating the feasible starting cells and target phenotypes.
(i) Reprogramming may involve the directed differentiation of human embryonic stem cells (hESCs)/induced pluripotent stem cells (iPSCs)
to a renal lineage. The iPSCs may be recipient-derived and may be derived from adult kidney cells or any other available adult cell type
using the same factors. Directed differentiation is likely to recapitulate development; hence, it is likely to require differentiation through a
nephron progenitor intermediate (induced nephron progenitor cell; iNP) but may continue on to more specific mature renal cell types.
(ii) A specific renal lineage may also be achieved via lineage-instructive reprogramming directly to that state from an adult cell type. Again,
this may be the renal epithelium, renal stroma, or any other available differentiated adult cell type; however, this is likely to be more
successful if the attractor states of the starting and target cell type are as close as possible. Reprogramming may be to the iNP state or
directly to a more mature renal cell fate. (iii) Finally, reprogramming may use the classical Yamanaka factors until the cells pass the point of
no return, after which a renal lineage may be reached via the application of the appropriate environmental cues. Such cues may once again
target the iNP state or aim to directly induce a more mature renal cell type.
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GOING DIRECTLY FROM NON-KIDNEY TO KIDNEY
The alternative approach, lineage reprogramming to the
preferred renal cell type directly from an adult cell, is growing
in credibility (see Table 1). Here the starting cell is an adult
cell, frequently a skin fibroblast, but the generation of a
pluripotent intermediate is not required. Instead, lineage-
instructive genes are overexpressed to drive the starting cell
toward the target attractor state. There are some caveats to
the current approach. Although most studies reporting iPSC
induction have started with primary cell isolates, much of the
classic lineage reprogramming studies have been conducted
in immortalized cell lines. Indeed, immortalized fibroblasts
are easier to reprogram than their primary counterparts.49 If
the ultimate intention is a cellular therapy, reprogramming
must be performed using primary cells. Another key feature
of the field has been the focus on generating target cell types
that are mature differentiated cells. This has the obvious
advantage that the target cells have readily identifiable
phenotypic characteristics (e.g., beating cardiomyocyte;
action potential–positive neurons) and frequently a well-
characterized attractor state, thereby identifying the specific
genes required. The generation of a progenitor cell type, such
as a nephron progenitor in the case of the kidney, has been
less common; however, several studies have now repro-
grammed fibroblasts directly to tissue-specific progenitor cells
using a combination of forced gene expression of carefully
controlled culture media conditions.50,51
CHOOSING A TARGET CELL TYPE: THE NEPHRON
PROGENITOR
Having discussed the reprogramming options now available,
we return to the issue of deciding what target cell to make
(Figure 2). In diseases such as type 1 diabetes or Parkinson’s
disease, replacement or restoration of the function of a single
cell type (b-islet cell or dopaminergic neuron, respectively) may
be sufficient to rescue the phenotype. For the kidney, the choice
of a target cell type is a major challenge. The entire epithelium
of the nephron arises from a single cell type, the nephron
progenitors of the developing kidney. The nephron progenitor
population is a developmentally specific pool of condensed
mesenchymal cells called cap mesenchyme (CM) located
around the tips of the branching collecting duct epithe-
lium.52,53 These cells behave as stem cells, undergoing self-
renewal in order to maintain the CM. The nephrons form from
these cells via a mesenchyme-to-epithelial transition (MET) to
form an epithelial renal vesicle. This structure elongates to
form comma-shaped and S-shaped bodies, which then pattern
and segment to form the functional nephron comprising
glomerulus, proximal tubule, loop of Henle, and distal tubule.
In the mammalian kidney, these nephron progenitors are
exhausted via differentiation before birth.54,55 Although this
population does not persist in the postnatal kidney,56 lineage
reprogramming of human cells to the nephron progenitor
phenotype represents an attractive possibility for the creation
of a cell source either able to elicit de novo nephrogenesis or be
Table 1 | Three different options for cellular reprogramming
Directed differentiation Lineage reprogramming
Culture-induced transdifferentiation of
partially reprogrammed cells
Source of
starting cells
ESC or iPS cells Any cell; most commonly fibroblast or
hematopoietic cell
Any cell; most commonly fibroblast or
hematopoietic cell
Genes involved Nil. Usually involves small compounds
or growth factors thought to
recapitulate normal differentiation
toward the desired end point
Specific transcription factors able to
direct a cell to a specific target
attractor state
Yamanaka factors
(Oct4, Sox2±Klf4, c-myc)
Advantages Entirely based on culture conditions,
therefore no genetic manipulation
Stepwise induction allows for
optimization of efficiency at each step
If starting with iPS, possible to generate
from the target patient thereby
ensuring a genetic match
Ultimately, may include genetic repair
of defective genes before
differentiation and delivery
Knowledge of intermediate cell culture
conditions is not required
Cells can transit directly from one
phenotype into another
Starting cell population could be
directly and readily sourced from target
patient
Does not rely on knowledge of target cell
gene regulatory network
Starting cell population could be directly
and readily sourced from target patient
Disadvantages No established differentiation
protocols for moving from human
pluripotent state to functional kidney
cell
Optimal final culture conditions for
target cell undefined
May include multiple steps each
requiring different factors to induce a
stepwise differentiation
Optimal final culture conditions for
target cell must be defined
Technique relies on knowledge of the
target cell gene regulatory network
Requires introduction or reactivation of
genes. This would ultimately need to
be a removable system to be approved
for use in man
Specific culture conditions able to select
for target cell type must be established
Requires knowledge of the kinetics of
partial reprogramming in order to define
the time window for transdifferentiation
Has the potential to also generate
unwanted pluripotent cells
Requires introduction or reactivation of
genes. This would ultimately need to be a
removable system to be approved for use
in man
Abbreviations: ESC, embryonic stem cell; iPS cell, induced pluripotent stem cell.
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differentiated further into multiple renal cell types. The first
barrier is to define the attractor state of this target cell type.
WHAT GENES WILL BE REQUIRED TO INDUCE NEPHRON
PROGENITORS?
The molecular networks thought to regulate CM specification,
self-renewal, and differentiation are dynamic and complex and
have been reviewed extensively elsewhere.57 Some of these
genes will be involved in specification of the CM, whereas
others may promote self-renewal, prevent death, or prevent
epithelialization. For reprogramming purposes, it will be
important to distinguish between transcriptional regulators
that are necessary for nephron progenitors and those that are
both necessary and lineage instructive. For example, Sall1 is
expressed in nephron progenitors58 and is necessary for kidney
development but may not be lineage instructive, as over-
expression of Sall1 in the committed Wnt4þ portion of the
CM had no effect on the differentiation of this subcompart-
ment.59 Fortunately, it is unlikely that every lineage-instructive
factor will be required for reprogramming. As long as
sufficient stimuli are provided to activate the endogenous
gene regulatory network, the cells may be gradually pulled into
the correct attractor state. Indeed, this has been the case in
iPSC reprogramming, where certain factors can be replaced or
even eliminated altogether.4,60,61
Many successful reprogramming studies have commenced
with a large number of potential lineage-instructive genes.
Indeed, the initial identification of factors able to induce
pluripotency started with a candidate list of 24 genes that were
ultimately narrowed to 4.3 As this will necessarily involve
screening many combinations, the development of a high-
content, robust screen of the target phenotype is a major
priority. This represents a barrier to the induction of any target
renal cell type, including nephron progenitors. The CM ‘niche’
is largely undefined, and there have been no successful reports
of the long-term survival of isolated CM in vitro.56,62,63 Both
fibroblast growth factor and bone morphogenetic protein sig-
naling appear to be important in survival of the CM.64–66
However, successful reprogramming does depend on the provision
of an appropriate environment.1,67 If the culture conditions do
not replicate the niche present within the nephrogenic zone of the
developing kidney, then even an appropriate set of reprogram-
ming genes may not induce nephron progenitor formation.
IT IS NOT THE JOURNEY BUT KNOWING WHEN YOU GET
THERE
According to reprogramming theory, there is no limit to the
distance that cells may traverse or the lineage boundaries they
may cross in order to change phenotype. However, there is
variability in the efficiency of iPSC reprogramming depending
upon the starting cell type, and the force with which you need
to impose a specific attractor state may vary. What is critical is
to prove that your reprogramming genes deliver the desired
phenotype and not some other end point. The key to success
appears to depend on two things: (i) the specificity of the
reprogramming genes to the desired attractor state and (ii) the
specificity of the assay for end point. Many transcription
factors expressed within the CM have other developmental
roles both in kidney, non-renal, and, indeed, non-mesodermal
tissues. Pax2, Eya1, and Six1, for example, have all been
implicated in the development of the inner ear,68–70 as well as
the brain and cranial placodes.71,72 Six1 and Eya1 are both
implicated in the development of the thymus73,74 and in
somitogenesis.75 This again emphasizes the need for a stringent
readout of the phenotype desired at the end of the
reprogramming event. Complete reprogramming to an
induced nephron progenitor phenotype must be assessed
functionally, as well as morphologically. However, there is a
lack of informative functional assays for nephron potential in
the field. Most assays have been developed to assess the ability
of an adult stem cell type to integrate into an existing nephron
in response to renal injury or to form renal tubular structures
under the renal capsule.76–78 This approach is not ideal, as it
does not necessarily provide the correct developmental context
for nephron progenitor survival and differentiation. We and
others have developed recombination assays in which
dissociated embryonic kidney is used to provide the necessary
developmental context to test integration and contribution of
nephron progenitors to an endogenous CM.56,79 By using this
assay, we have been able to analyze the functional contribution
of test cell populations to the nephron progenitor compart-
ment of ex vivo organoid cultures.56
MATCHING CELL TYPE TO DISEASE STATE
A major challenge would be whether induced nephron
progenitors were able to survive in a postnatal kidney,
let alone contribute to existing adult nephrons and/or
generate new nephrons. The observation that neonephrogen-
esis from a persistent nephron progenitor population does
occur in the adult zebrafish, including normal patterning,
segmentation, and fusion with the collecting duct, brings
hope.80 In mammals, the reactivation of key developmental
genes, such as Pax2 (ref. 81) and others,82 does imply that
recapitulation of development within the tubular epithelium
itself might be feasible, but neonephrogenesis may not. If an
induced nephron progenitor population cannot survive and
differentiate in the adult kidney, it may be necessary to
choose a different target cell. As noted previously, different
cells may be required for different renal disease states. Table 2
identifies the distinct cell types affected in a variety of
hereditary renal diseases. Coupling gene correction with
reprogramming to the specifically required differentiated cell
type may finally provide a strategy for the treatment of
inherited renal disorders, including ciliopathies and nephro-
tic syndromes. However, the introduction of such cell types
into the mature kidney remains a formidable barrier.
Although we know that the Six2þ CM gives rise to all other
cells within the mature nephron, whether there is a
subsequent hierarchy of segment-specific or pan-nephron
epithelial progenitors that exist between the CM state and the
mature cell types is not known. However, such intermediate
cell types (immature podocyte, immature proximal tubule
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cells, pan-nephron epithelia) may also represent promising
target cells for reprogramming strategies. Such intermediate
cell types that are already epithelia may be more easily
encouraged to adopt appropriate differentiated states if
reintroduced into an adult tissue. We have begun to define
the expression profile of intermediate states of early nephron
epithelia83 potentially defining appropriate lineage-instruc-
tive genes for such reprogramming targets. The knowledge in
the field with respect to the growth factors able to support
distinct tubular segments will also be valuable in attempts to
reprogram to these more specific target cell types.
CUTTING TO THE CHASE: ANOTHER OPTION
To date, we have proposed directed differentiation or lineage
reprogramming as options for generating nephron progeni-
tors. There is, however, a third option now proving feasible:
culture-induced transdifferentiation of partially reprogrammed
cells using the four iPSC factors (see Table 1). The induction
of pluripotency using Oct2, Sox2, c-myc, and Klf4 does not
appear to involve an ordered retracing of the specific
differentiative events experienced by that starting cell
population during embryogenesis. Indeed, the expression of
the reprogramming factors is no longer required once the
epigenetic state of the donor cell moves that cell out of its
initial attractor state. The withdrawal of the reprogramming
factors after this ‘point of no return’ places the cells in a state
of indecision facetiously referred to as ‘Area 51’.84 Guaranteed
progression to the successful generation of iPSCs requires a
longer period of expression of the four key reprogramming
factors past a point referred to as the ‘point of commitment’.
Nagy and Nagy84 predicted that rather than these genes
specifically imposing pluripotency, they created an epigenetic
state in which other factors played a role in dictating the
outcome for individual cells. This is supported by observa-
tions of occasional colonies of beating cardiomyocytes arising
spontaneously during the generation of iPSCs.85 This also
predicts that cells in this state may be diverted to alternative
fates, potentially allowing the generation of a wide variety of
cell phenotypes using the same four genes. This prediction
has proven accurate with the conversion of fibroblasts to
cardiomyocytes, neuronal progenitors, and hematopoietic
progenitors using some or all of the same genes as those used
to generate iPSCs.50,51,85 In such studies, the key determinant
of ultimate cellular phenotype was the culture conditions
provided to these cells during reprogramming, not the
transcription factors themselves. For example, hematopoetic
progenitors were generated via Oct4-mediated reprogram-
ming with subsequent culture in stem cell factor and FMS-
like tyrosine kinase 3 ligand.50 The implications for the
kidney are exciting. This approach removes the need to define
the specific transcriptional network required for reprogram-
ming to a specific attractor state, requiring instead an
appropriate media able to select for the renal cell type
required. An understanding of the growth factors involved in
defining and maintaining the required cell type is needed for
this approach. A strong identifying phenotype, such as
beating in a culture dish in the case of cardiomyocytes, would
also make this approach more likely to succeed. In some
instances, such information is already available for more
mature renal target cell populations, such as the podocyte. In
contrast, the challenge of this approach for the generation of
nephron progenitors is again our lack of understanding of the
growth factors able to support and sustain this phenotype.
CONCLUSION
We have discussed here a variety of nuclear reprogramming
options for the generation of nephron progenitors or more
mature renal cell types. Although these would have been
deemed fiction 5 years ago, the pace with which the field
advances makes it likely that one or more such approaches
will prove fruitful for the renal field in the short term. There
remains a chasm between such scientific breakthroughs and
Table 2 | Defining the appropriate target cell for different renal diseases
Renal disease Podocytea
Pan-nephron
epithelial
progenitora
Proximal
tubular
epitheliuma
Distal tubular/
LOH tubular
epitheliuma
Collecting
duct
epithelium
Mesangial
cells
Polycystic kidney disease
(ADPKD, ARPKD)
Alport syndrome, nephrotic syndrome
(NPHS1/2), other podocyte defects
Cystic diseases; ciliopathies
Dent’s disease, cystinosis, Lowe
syndrome
Gitelman syndrome, distal tubular
acidosis
Diabetes insipidus
Denys Drash syndrome; Frasier syndrome,
other inherited forms of FSGS or MS
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; ARPKD, autosomal recessive polycystic kidney disease; FSGS, focal segmental glomerulosclerosis;
LOH, loop of Henle; MS, mesangial sclerosis.
Different hereditary defects affect different renal cell types.86 Shading represents the preferred target cell type to be generated via reprogramming for the treatment of each
of these forms of renal disease.
aDerived from cap mesenchyme/nephron progenitors.
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clinical delivery. Nevertheless, for the renal failure patient, the
hope that comes with potential changes in treatment options
is substantial.
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